Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
On 24 October 2015, during the HFA Summit, members of the Heart Failure Association Board and national Heart Failure Working Group Presidents signed a declaration designed to unanimously adopt a Call For Action in support of the HFA's Global Heart Failure Awareness Programme.
The HFA, the world’s largest heart failure organisation and heart failure working groups from national cardiac societies join forces to recommend united action, and declare that they believe that the global burden of heart failure is huge, and cannot be allowed to continue unchallenged. Preventing heart failure must become a strategic health priority for each and every country
Read the Declaration
The HFA White Paper "Heart failure: Preventing disease and death worldwide" (click to download) is available.
The White Paper aims to demonstrate the burden of the disease with a clear Call to Action which includes the establishment of a systematic approach to identifying target groups at risk from heart failure and appropriate prevention and treatment modalities which could serve as the basis for future international guidelines.
It has been distributed and presented to National Heart Failure Societies and Working Groups worldwide at the Endorsement Meeting that took place in Athens on 16 May 2014.
Listen to Prof Petar Seferovic (Belgrade, RS) and Prof Piotr Ponikowski (Wroslaw, PL) discussing the aims and challenges of the HF Global Awareness Programme.
The complexity of the heart failure syndrome represents a major obstacle to adequate identification and diagnosis of untreated patients. But this also thwarts understanding of heart failure among politicians and the general public.
Heart failure awareness among healthcare professionals and non-medics is poor across the globe, in contrast to the recognition of cancer which is related to the global campaign oncologists have been conducting for some time.
Heart failure is a preventable disease.
Recent advances in therapy result in much better outcomes for patients which also make heart failure a treatable disease.
Heart failure treatment is seen differently according to geographical location.
There is clear evidence that the prevalence of heart failure will rise substantially over the next 20-30 years thus increasing the economic burden of prevention and treatment on society.
The unique combination of complementary partners at national, European and world levels is the most effective way to reach the objectives of this project. This partnership can be expressed as a synergy of public heart failure awareness and strategic and political expertise.
The wide scope of the project led the World Heart Failure Alliance to prioritize its actions. It was agreed by the partners that the first two targets to reach are policy makers and patient with heart failure risk.
The first step of this ambitious programme took place in December 2013:
The publication of the 'Acute Heart Failure Report - Improving Care for Patients with Acute Heart Failure'. The recommendations contained in this report have been endorsed and adopted by the Heart Failure Association of the European Society of Cardiology as part of their Global Heart Failure Awareness Programme.
Thereon, the programme will be broken down into 2 phases:
Phase 1: 2013-2015Phase 1 is divided into several steps: Write the white paper/call for action on heart failure Endorsement and Dissemination of the white paper on heart failure Prepare Phase 2 of the projectPhase 2: 2016-2018 - Strategy• Use White Paper as the scientific rationale and Call to Action for advancing clinical practice globally in heart failure management• Drive widespread awareness through media publicity and by generating scientific publications to amplify new information• Enroll primary care physicians in earlier detection of HF patients by designing an HFA Patient activation plan and integrating this into HF Guidelines• Formalise HF management within cardiac clinical practice in all countries through HFA accredited education and certification (physicians and nurses)• Create health economic evidence to engage policy makers, government representatives• Continue to work with National HF societies to support country initiatives
Read the meeting report.
Phase 2 actions will be adjusted according to the result of Phase 1.
ProponentsThe Heart Failure Association of the ESC (HFA) designed the Global Heart Failure Awareness Programme. It is to be lead by the HFA (with its network of 40 National Heart Failure Societies), with the support of high-level representatives of heart failure groups in the European Society of Cardiology, the Heart Failure Society of America, the Heart Failure Society of South Africa, the Japanese Heart Failure Society and groups in Brazil, Saudi Arabia, China, Indonesia, Australia and New Zealand.If you are an organisation interested in joining the Global Heart Failure Awareness Programme, please contact us.The Global Heart Failure Awareness Programme is supported by Novartis Pharma AG and SERVIER in the form of an unrestricted educational grant.
© 2017 European Society of Cardiology. All rights reserved